Rationale Minocycline, a tetracycline antibiotic, interacts with brain glutamate and dopamine neurotransmission. In preclinical studies, minocycline attenuated amphetamineinduced acute dopamine release and subsequent behavioral sensitization. The goal of this study was to determine minocycline's effects on the acute physiological, behavioral, and subjective responses to dextroamphetamine (DAMP) in healthy volunteers. Methods Ten healthy volunteers participated in an outpatient double-blind, placebo-controlled, crossover study. Subjects had a 5-day treatment period with either minocycline (200 mg/day) or placebo and then were crossed over for 5 days of the other treatment. After 2 days of taking the study medication, on days 3 and 4, subjects were randomly assigned to double-blind acute challenge with either 20 mg/70 kg DAMP or placebo DAMP (randomly labeled as drug A or B) and then crossed over to the other challenge. On day 5 (experimental session 3), subjects had the opportunity to selfadminister either placebo or DAMP capsules by working on a progressive ratio computer task. Results Minocycline attenuated DAMP-induced subjective rewarding effects but did not change DAMP choice behavior. Minocycline treatment speeded reaction times on a Go No-Go task and reduced plasma cortisol levels. Conclusions These findings warrant further studies examining the potential use of minocycline for stimulant addiction.
Introduction
A growing body of evidence suggests that glutamate, in conjunction with dopamine, is essential in mediating the rewarding and addictive effects of psychostimulants, amphetamines, and cocaine (Kalivas 2007) . Glutamatergic input to the ventral tegmental area (VTA) or nucleus accumbens enhances dopaminergic transmission in the mesocorticolimbic pathway (Tzschentke and Schmidt 2003) . The glutamatergic input to the VTA are strengthened within hours following a single cocaine administration (Ungless et al. 2001) . Blockage of N-methyl D-aspartate (NMDA)-or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors prevents behavioral sensitization or reinstatement of psychostimulant use in preclinical models of addiction (Cornish and Kalivas 2000; Di Ciano and Everitt 2001; Knackstedt and Kalivas 2009; Vezina and Queen 2000) . Since glutamate is the primary neurotransmitter for learning and memory, its simultaneous activation with the dopaminergic system may underlie the changes in neuronal plasticity that lead to the initiation of addiction (Thomas et al. 2008) .
The contribution of glutamate activation to psychostimulant responses has not been well characterized in humans partly due to the limited number of glutamatergic medications available for human use. One of these medications is minocycline, an antibiotic derived from tetracycline and commonly used to treat acne. Minocycline readily crosses the blood-brain barrier and has significant effects on dopamine and glutamate transmission. In preclinical studies, minocycline attenuated the development of behavioral sensitization to amphetamines (Kofman et al. 1990; Zhang et al. 2006 ) and cocaine (Chen et al. 2009 ) as well as dopamine-releasing effects of amphetamines in the striatum (Zhang et al. 2006) . The inhibitory effects of minocycline on amphetamine-induced dopaminergic activation are possibly mediated by its glutamatergic actions. Minocycline blocked the behavioral responses mediated by the NMDA-type glutamate receptor in mice (Fujita et al. 2008 ) and rats (Levkovitz et al. 2007; Munzar et al. 2002) . Furthermore, minocycline attenuated the reduction of dopamine transporters produced by repeated administration of methamphetamine in the monkey brain (Hashimoto et al. 2007) . In other studies, minocycline reduced glutamate release in hippocampal neurons of rats (Gonzalez et al. 2007 ) and increased phosphorylation and surface expression of GluR 1 -type AMPA receptor subunits in mouse striatal neurons (Imbesi et al. 2008) . Minocycline is being examined for the treatment of methamphetamine addiction, depression, schizophrenia, and neurodegenerative disorders including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (Chaves et al. 2009; Hashimoto 2009; Levkovitz et al. 2009; Molina-Hernandez et al. 2008) .
In spite of its potential use as a novel treatment medication for several psychiatric disorders, the behavioral pharmacology of minocycline has not been well characterized in humans. In this study, we investigated minocycline's effects on physiological, cognitive, subjective, and behavioral responses to amphetamines. Amphetamines activate the mesocorticolimbic dopamine system, an essential component of the brain reward circuit (Bardo 1998; Koob 1992; Tzschentke 2001 ). Based on the preclinical studies indicating inhibition of behavioral and neurochemical responses of amphetamine by minocycline, we hypothesized that minocycline would attenuate the subjective rewarding effects of oral dextroamphetamine (DAMP) and improve cognitive performance. We also hypothesized that minocycline would reduce DAMP reinforcement, as assessed with an amphetamine choice paradigm.
Materials and methods

Participants
A total of 15 healthy controls were recruited from the New Haven area by newspaper advertisements and flyers. Five of 15 dropped out before completing the study because of a positive urine toxicology (n=1), cold symptoms (n=2), and personal reasons (n=2). The ten completers were eight males and two females (seven African-Americans, two Caucasians, and one Hispanic) with an average age (SD) of 33.7 years (7.7). All subjects had normal physical, laboratory, and psychiatric examinations, and none were dependent on alcohol or other drugs except nicotine. In order to minimize confounding effects from nicotine or caffeine withdrawal, those who smoked more than five cigarettes or drank more than three cups of caffeinated beverages per day were excluded. All subjects provided informed consent prior to study entry and were paid for participation. Experimental sessions were conducted in the Biostudies Unit located at the VA Connecticut Healthcare System, West Haven campus. This study was approved by the VA Connecticut Healthcare System Human Subjects Subcommittee.
Procedures
In this double-blind, placebo-controlled crossover study, subjects had two 5-day treatment periods in which they were randomized to minocycline (200 mg/day) or placebo. Each treatment period was separated by a minimum 4-day "washout" period in order to minimize residual effects from study medications. During the first 2 days of each treatment period, subjects had daily morning clinic visits at about 8:00 A.M. for medication administration and monitoring of adverse events. On days 3 and 4, subjects came to the laboratory for experimental sessions 1 and 2. In these sessions, subjects received a random order of placebo or 20 mg/70 kg DAMP (randomly labeled as drug A or B) in a double-blind fashion. At the start of sessions 1 and 2, an indwelling intravenous catheter was placed in the antecubital vein both for blood drawing and as a safety precaution. Baseline measures were obtained, and then subjects were given that day's dose of the study medication (minocycline or placebo) and DAMP followed by a light meal. Outcome measures were collected over 4 h of the experimental session.
On day 5 (experimental session 3), subjects had the opportunity to self-administer either drug A or drug B (placebo or DAMP) capsules working on a progressive ratio computer task adapted from Stoops et al. (2004 and . For this task, subjects first chose on the computer screen whether they wanted to work for drug A or B. Subjects then had the option to earn 1/4 of the medication dose (5 mg for DAMP) by pressing the A or B button of the keyboard 200 times. If subjects wanted to work on getting another capsule, they had to press the keyboard 400 for the second, 800 for the third, and 1,600 times for the fourth, which was the maximum number of capsules (20 mg for DAMP) allowed. All experimental sessions started at 8:00 A.M. and urine toxicology screenings were done before each session. Drugs DAMP (the dextrorotatory isomer of amphetamine) was obtained from Barr Laboratories (Pomona, New York). DAMP is used for the treatment of attention deficit hyperactivity disorder and narcolepsy at a dose of 5-60 mg/day (PDR 2009). In this study, we used a single 20 mg/70 kg oral dose which has been shown to produce typical amphetamine effects in healthy volunteers (Brauer and de Wit 1996; Fillmore et al. 2003; Sofuoglu et al. 2008a, b; Tidey et al. 2000) . Plasma levels of DAMP peak within 1 to 3 h following oral administration, and the elimination half-life is 10-13 h (PDR 2009).
Minocycline (Dynacin®) was administered at 200 mg/day, as a single dose, for 4 days. This dose is within the range of usual daily dose of minocycline used for the treatment of infections (Jonas and Cunha 1982) . Further, two recent trials have utilized a 200-mg/day dose of minocycline in studies of stroke and schizophrenia (Lampl et al. 2007; Levkovitz et al. 2009 ; The NINDS NET-PD Investigators 2006). Following oral administration, peak plasma levels of minocycline are reached within 1-4 h. The elimination half-life of minocycline ranges from 11 to 24 h. Minocycline was administered in the clinic daily by the study nurse.
Measures
The outcome measures included physiological, endocrine, subjective, behavioral, and cognitive performance measures. The physiological measures consisted of systolic and diastolic blood pressure and heart rate which were measured at baseline then at 30, 60, 90, 120, 150, and 180 min after DAMP administration. Plasma cortisol was obtained at baseline and then at 1, 2, and 3 h after DAMP administration. Cortisol release is sensitive to DAMP through central noradrenergic pathways (Grady et al. 1996; Seiden et al. 1993) .
Subjective measures were obtained at baseline and then at 30, 60, 90, 150, and 180 min after the medication treatment and were comprised of the Drug Effects Questionnaire (DEQ), the Addiction Research Center Inventory-Short Form (ARCI), and the Profile of Mood States (POMS). The DEQ assessed the acute subjective effects of DAMP and asked subjects to rate "stimulated", "high", "anxious", "sedated", "down", "feeling the drug strength", "feel good drug effects", "feel bad drug effects", "want more drug", and "like the drug" on a 100-mm scale from 0 ("not at all") to 100 ("extremely"). The ARCI consists of 49 true-or-false questions with five subscales: drug-induced euphoria (morphine-benzedrine group; MBG), stimulant-like effects (amphetamine; A), intellectual efficiency and energy (benzedrine group; BG), dysphoria (lysergic acid), and sedation (pentobarbital-chlorpromazine; PCAG) (Martin et al. 1971 ). The POMS is a 65-item rating scale used to measure the effects of medication treatments on mood using six subscales: tension, depression, anger, vigor, fatigue, and confusion (McNair et al. 1971) .
The behavioral outcome was the number of capsules subjects earned for self-administration on day 5 of each treatment period. Cognitive performance was assessed with the sustained attention to response test (SART) which was administered 2 h after DAMP administration. The SART (Robertson et al. 1997 ) is a Go No-Go task. It assesses the ability to withhold responses to an infrequently occurring target (No-Go trials). Reaction times (RTs) and errors on Go trials are also assessed. Two hundred twenty-five single digits (25×9 digits) are presented on a computer monitor for 250 ms each, immediately followed by a mask for 900 ms. Subjects must press a spacebar in response to every digit except the "3". They are instructed to give equal importance to speed and accuracy (see (Sofuoglu et al. 2008b ) for details).
Statistical analysis
To assess treatment effects, we used a mixed-effect repeated measures crossover analysis using SAS Proc Mixed (version 9.1.3.). The structure of the analysis included fixed main effects for level of minocycline (placebo or minocycline), DAMP (DAMP or placebo), the time point of the measure after giving DAMP or placebo, and the interaction of the main effects of minocycline or placebo and DAMP or placebo. Also included were a random effect participant and a blocking factor for treatment sequence. On the SART, the primary outcome measure was the number of errors of commission (out of 25) pressing the spacebar when "3" was displayed. The number of errors of omission (not pressing the spacebar on digits other than 3) and the mean correct reaction times to those digits were also measured, with reaction times quicker than 100 ms discarded from analysis. A significance level of p<0.05 was used for all analyses.
Results
Physiological responses
As shown in Fig. 1 , DAMP increased the heart rate (DAMP main effect; F(1, 265)=15.2; p<0.001), systolic (DAMP main effect; F(1, 265)=42.9; p<0.0001) and diastolic blood pressure (DAMP main effect; F(1, 265)=23.5; p<0.0001) compared to placebo. Minocycline, compared to placebo, increased the systolic blood pressure (minocycline main effect; F(1, 265)=5.1; p<0.05). Minocycline did not affect the daily baseline heart rate, systolic or diastolic blood during the treatment phase (ps>0.05).
Subjective responses DAMP increased the rating of "feel the drug strength" (DAMP main effect; F(1, 225)=25.4; p<0.0001), "feel good drug effects" (DAMP main effect; F(1, 225)=18.4; p< 0.0001), "feel high" (DAMP main effect; F(1, 225)=18.8; p<0.0001), and "want more drug" (DAMP main effect; F (1, 225) = 4.5; p < 0.05) items of the DEQ (Fig. 2) . Minocycline + DAMP, compared to DAMP, significantly reduced the rating of "feel good drug effects" (minocycline-by-DAMP; F(1, 225)= 11.5; p<0.001) and "feel high" (minocycline-by-DAMP; F(1, 225)=13.4 p<0.001).
DAMP significantly increased the scores of the BG (DAMP main effect; F(1, 221)=24.9; p<0.0001), MBG (DAMP main effect; F(1, 221)=24.9; p<0.0001), and A 30, 60, 90, 120, 150 , and 180 min after DAMP administration. A significant minocycline-by-DAMP interaction was observed for "feel good drug effects" and "feel high" (p<0.05) (DAMP main effect; F(1, 221)=50.4; p<0.0001) subscales of the ARCI (Fig. 3) . Minocycline + DAMP reduced the scores on the A subscale compared to DAMP (minocyclineby-DAMP; F(1, 221)=3.7; p=0.05).
Systolic Pressure
DAMP reduced scores for fatigue (DAMP main effect; F (1, 221)=7.8; p<0.01) and increased scores for vigor (DAMP main effect; F(1, 221)=11.4; p<0.001) subscales of the POMS. DAMP reduced the scores for fatigue, (DAMP-by-minocycline interaction; F(1, 221)=6.4; p< 0.05) compared to the DAMP placebo.
Endocrine responses
As shown in Fig. 4 , DAMP increased cortisol responses relative to placebo DAMP (main effect of DAMP; F(1, 140)=27.5; p<0.0001), while minocycline reduced them (main effect of minocycline; F(1, 138)=5.1; p<0.05).
Sustained attention to response test
Summary statistics on the SART are summarized in Table 1 . Under minocycline treatment, the reaction times were faster (main effects of minocycline; F(1, 26)=4.52, p<0.05).
Drug choice task
Minocycline did not affect DAMP choice behavior, with 60% of the subjects choosing no drug under minocycline or placebo condition. Under placebo condition, 40% of the subjects chose one or more doses of DAMP. In comparison, under minocycline treatment, 10% chose one or more doses of DAMP and 30 chose placebo (p>0.05). stimulant-like effects (A), and intellectual efficiency and energy (BG) subscales of ARCI, and rating of "good drug effects", "high", and "want more drug" items of the DEQ. Minocycline attenuated some of DAMP's subjective rewarding effects including the "high" and "feel good drug effects" items of the DEQ and the stimulant-like effects (A) subscale in the ARCI. In a recent study, minocycline did not change the subjective effects from intravenous nicotine (Sofuoglu et al. 2009 ), suggesting that minocycline does not attenuate the subjective effects of all dopamine-releasing agents like nicotine. Consistent with our findings, acute minocycline treatment attenuated DAMP-induced locomotor activity in rats (Kofman et al. 1990 (Kofman et al. , 1993 and prevented development of behavioral sensitization to methamphetamine (Mizoguchi et al. 2008; Zhang et al. 2006) or cocaine (Chen et al. 2009 ). Further, using in vivo microdialysis technique, Zhang et al. (2006) have shown that minocycline reduced methamphetamineinduced striatal dopamine release in mice. Dopamine release in striatum is a critical step for the rewarding effects of stimulants (Volkow et al. 1997) and its reduction by minocycline may explain attenuation of DAMP's subjective effects by minocycline. Minocycline also improved reaction time in the SART test. Previous preclinical and clinical studies have demonstrated the cognitive-enhancing effects of minocycline. In preclinical studies, minocycline improved methamphetamine-induced impairment on an object recognition task in mice (Fujita et al. 2008) . It also reversed deficits in visuospatial memory and sensorimotor gating induced by the NMDA antagonist PCP in rats (Levkovitz et al. 2007 ). In schizophrenic individuals, 200 mg/day of minocycline also improved executive functions including working memory, cognitive shifting, and cognitive planning functions (Levkovitz et al. 2009 ).
Minocycline did not change self-administration of DAMP in our choice procedure although it attenuated the subjective rewarding effects of DAMP. Consistent with our findings, previous studies reported dissociation between subjective drug effects and drug self-administration in humans (Dudish-Poulsen and Hatsukami 1997; Haney and Spealman 2008) . One caveat was that our subjects were healthy volunteers who had a low rate of drug administration and chose no drugs for 60% of the options. In future studies, minocycline's effects on DAMP choice behavior can be examined in those with a history of stimulant use. Minocycline also reduced the cortisol levels following DAMP or placebo administration in healthy volunteers, suggesting direct inhibitory effects of minocycline on cortisol release. Reduction of either dopamine or glutamate input to the paraventricular area of the hypothalamus may result in reduced CRH release (Patchev et al. 1994; Ziegler et al. 2005) . Minocycline increased DAMP-induced systolic blood pressure elevations. We are not aware of previous studies showing blood pressure increases induced by minocycline.
The mechanism by which minocycline attenuates the subjective and cortisol responses to DAMP is unknown. One possibility is enhancing AMPA transmission by increasing phosphorylation and surface expression of the AMPA receptor subunit GluR 1 (Imbesi et al. 2008) . Increased GluR 1 phosphorylation facilitates learning and memory and is a medication development target for cognitive disorders, schizophrenia, and depression. Studies also indicate that activation of GluR 1 receptors may prevent sensitization to stimulants. However, not consistent with this possibility, another medication, riluzole, with similar GluR 1 -activating effects, enhanced the subjective effects of DAMP and increased errors of commission on the SART test in healthy controls (Sofuoglu 2008b) . Additionally, clinically used doses of minocycline inhibit nitric oxide (NO) synthesis (Kim et al. 2004; Sadowski and Steinmeyer 2001) . NMDA-type glutamate receptor activation releases NO as a second messenger that facilitates glutamate release and increased dopamine release into the nucleus accumbens (Itzhak and Ali 2006) . This inhibition of the NO second messenger system opens possibilities for further medication development with other compounds.
Our study has several other treatment implications. First, minocycline's attenuation of the subjective rewarding effects of DAMP, together with the promising preclinical studies summarized above, supports its use for stimulant addiction. Recently, Tanibuchi et al. (2010) reported a case showing that minocycline is effective in a patient with a methamphetamine-related psychotic disorder. Thus, controlled efficacy studies of minocycline in cocaine-or methamphetamine-addicted individuals are warranted. Second, improvement of the reaction time in the SART is consistent with minocycline's cognitive-enhancing effects that were previously observed in both preclinical and clinical studies. Minocyline is currently under investigation for neurocognitive disorders, although a multicenter study with ALS patients found a more rapid cognitive decline in minocycline-treated patients (up to 400 mg/day; Gordon et al. 2007 ). Other studies suggested that a lower dose of 200 mg/day is safer in this population (Leigh et al. 2008 ).
Ongoing clinical trials should help to establish the safety of minocycline in different patient populations. This study had several limitations. First, this study did not examine the dose-dependent effects of minocycline since only 200 mg/day dose was used. Second, similarly the study did not examine minocycline's effects on dosedependent dextroamphetamine responses since only 20 mg dose of dextroamphetamine was used. Lastly, our subjects were healthy controls and the generalization of these findings to stimulant users need to be demonstrated.
In summary, 200 mg/day of minocycline attenuated some of the subjective rewarding responses to DAMP and reduced cortisol levels in healthy controls. Minocycline also speeded reaction times on a sustained attention task. Further studies are warranted to examine the therapeutic utility of minocycline as a treatment medication for stimulant addiction and as a cognitive enhancer.
